Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MMP1 | P03956 | 1/20 | 0.32 |
| ▸ | MMP9 | P14780 | 1/20 | 0.32 |
| ▸ | MMP13 | P45452 | 1/20 | 0.32 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.30 |
| ▸ | MGAM | O43451 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | SI | P14410 | 1/20 | 0.30 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL770755 | 0.89 | CYP2C19 (0.39) | MAPTCYP2C19POLBTDP1ALDH1A1 | |
| SCHEMBL32679949 | 0.87 | MAPT (0.38) | MAPTCYP2C19POLBTDP1 | |
| SCHEMBL7975198 | 0.83 | MAPT (0.39) | MAPTCYP2C19POLBTDP1ALDH1A1 | |
| SCHEMBL6831466 | 0.82 | ALDH1A1 (0.38) | MAPTALDH1A1 | |
| SCHEMBL4740338 | 0.80 | MEN1 (0.42) | MAPTCYP2C19ALDH1A1LMNAMGAM | |
| SCHEMBL11133055 | 0.80 | LMNA (0.39) | MAPTCYP2C19POLBTDP1ALDH1A1 | |
| SCHEMBL28248731 | 0.80 | CYP2C19 (0.38) | MAPTCYP2C19POLBTDP1ALDH1A1 | |
| SCHEMBL28554030 | 0.79 | MAPT (0.36) | MAPTCYP2C19POLBTDP1ALDH1A1 | |
| SCHEMBL27893535 | 0.77 | CYP2C19 (0.33) | MAPTCYP2C19POLBTDP1ALDH1A1 | |
| SCHEMBL28248734 | 0.77 | TSHR (0.35) | MAPTCYP2C19POLBTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9683123-B2 | Silver ink | PESOLVE CO., LTD. (KR) | 2017-06-20 | — | — | US | disclosed |
| US-20160168408-A1 | SILVER INK | PESOLVE CO., LTD. (KR) | 2016-06-16 | — | — | US | disclosed |
| US-5101070-A | From an acetoacetic acid ester; by-product minimization | NIPPON GOHSEI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1992-03-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168408-A1 | SILVER INK | TP53, MKI67, NRAS | MAPT 1151/4885CYP2C19 1013/4885POLB 1687/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.